Managing non-acute subdural hematoma using liquid materials: a Chinese randomized trial of middle meningeal artery treatment (MAGIC-MT)—protocol

Simple item page
dc.contributor.authorZuo, Qiao
dc.contributor.authorNi, Wei
dc.contributor.authorYang, Pengfei
dc.contributor.authorGu, Yuxiang
dc.contributor.authorYu, Ying
dc.contributor.authorYang, Heng
dc.contributor.authorMajoie, Charles B. L. M.
dc.contributor.authorGoyal, Mayank
dc.contributor.authorLiu, Jianmin
dc.contributor.authorMao, Ying
dc.date.accessioned2023-09-17T00:03:19Z
dc.date.available2023-09-17T00:03:19Z
dc.date.issued2023-09-14
dc.date.updated2023-09-17T00:03:19Z
dc.description.abstractAbstract Background The conventional treatments for non-acute subdural hematoma (SDH) are facing the challenge of high hematoma recurrence and progression. A novel treatment of middle meningeal artery (MMA) embolization showed the potential role in decreasing the recurrence and progression rate of SDH compared to conventional treatments in multiple cohort studies. A randomized controlled trial is warranted to determine the effectiveness and safety of MMA embolization for non-acute hematoma and whether MMA embolization is superior to conventional treatments to lower the symptomatic recurrence and progression rate of non-acute SDH. Methods This is an investigator-initiated, multi-center, prospective, open-label parallel group trial with blinded outcome assessment (PROBE design) assessing superiority of MMA embolization compared to conventional treatments. A total of 722 patients are planned to be randomized 1:1 to receive MMA embolization (intervention) or conventional treatments (control). The primary outcome is the symptomatic SDH recurrence/progression rate within 90 ± 14 days post-randomization. Discussion This trial will clarify whether MMA embolization could reduce the recurrence or progression rate of symptomatic non-acute SDH compared to conventional treatment. Trial registration ClinicalTrials.gov. Identifier: NCT04700345, Registered on 7 January 2021.
dc.identifier.citationTrials. 2023 Sep 14;24(1):586
dc.identifier.urihttps://doi.org/10.1186/s13063-023-07608-2
dc.identifier.urihttps://hdl.handle.net/1880/117081
dc.identifier.urihttps://doi.org/10.11575/PRISM/41925
dc.language.rfc3066en
dc.rights.holderBioMed Central Ltd., part of Springer Nature
dc.titleManaging non-acute subdural hematoma using liquid materials: a Chinese randomized trial of middle meningeal artery treatment (MAGIC-MT)—protocol
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
13063_2023_Article_7608.pdf
Size:
1.04 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.25 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications